NCT06316414View on ClinicalTrials.gov

Omalizumab in Severe Asthmatics With Food Allergy

CompletedOBSERVATIONAL
Enrollment

65

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Food; Allergy, Anaphylactic ShockAsthma in Children
Interventions
BIOLOGICAL

Omalizumab

Administration of Omalizumab at the doses indicated for asthma in the EMA information leaflet.

Trial Locations (1)

00145

Pediatric Hospital Bambino Gesù IRCCS - Allergy Dpt, Roma

All Listed Sponsors
lead

Bambino Gesù Hospital and Research Institute

OTHER

NCT06316414 - Omalizumab in Severe Asthmatics With Food Allergy | Biotech Hunter | Biotech Hunter